| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
5-Aza-7-deazaguanine targets purine nucleoside phosphorylase (PNP), an enzyme that catalyzes the reversible phosphorolysis of purine nucleosides. The compound serves as a substrate for wild-type E. coli PNP and its Ser90Ala mutant. By acting as a substrate for PNP, 5-Aza-7-deazaguanine is used in the enzymatic synthesis of base-modified nucleosides. These modified nucleosides are valuable tools for studying nucleic acid structure, function, and for developing nucleoside-based therapeutics.
|
|---|---|
| ln Vitro |
In vitro studies have demonstrated that 5-Aza-7-deazaguanine is a substrate for wild-type E. coli purine nucleoside phosphorylase and its Ser90Ala mutant. The compound is used in enzymatic reactions to synthesize base-modified nucleosides. As a substrate, it is converted by PNP into modified nucleosides that can be incorporated into nucleic acids or used as therapeutic agents. However, specific in vitro activity data such as kinetic parameters (Km, Vmax) are not widely available in the published literature.
|
| ln Vivo |
In vivo studies on 5-Aza-7-deazaguanine are limited, as the compound is primarily used as a research tool for in vitro enzymatic synthesis of modified nucleosides. The compound is not intended for therapeutic use and is primarily used in biochemical research. However, modified nucleosides synthesized using 5-Aza-7-deazaguanine as a substrate may have potential therapeutic applications, including antiviral and anticancer therapies. Specific in vivo data for 5-Aza-7-deazaguanine itself are not available.
|
| Enzyme Assay |
The in vitro enzyme assays for 5-Aza-7-deazaguanine typically involve measuring its activity as a substrate for purine nucleoside phosphorylase. In these assays, the compound is incubated with PNP and a phosphate donor, and the formation of the modified nucleoside product is monitored using HPLC, LC-MS, or UV spectrophotometry. Kinetic parameters such as Km and Vmax can be determined from substrate concentration versus reaction velocity curves. These assays are standard for characterizing the substrate properties of purine analogs for PNP.
|
| Cell Assay |
Cellular assays for 5-Aza-7-deazaguanine are limited, as the compound is primarily used as an enzymatic substrate rather than for direct cellular studies. However, the compound's effects on cells can be studied by treating cells with the modified nucleosides synthesized from 5-Aza-7-deazaguanine. These modified nucleosides may be incorporated into cellular nucleic acids and affect cell viability, proliferation, or gene expression. However, specific cell-based protocols for 5-Aza-7-deazaguanine itself are not widely published.
|
| Animal Protocol |
In vivo animal studies for 5-Aza-7-deazaguanine are not well-documented. As a research compound used primarily for enzymatic synthesis, the compound has not been studied in animal models. However, modified nucleosides synthesized using 5-Aza-7-deazaguanine as a substrate may be evaluated in animal models for their therapeutic potential. Researchers interested in studying the in vivo effects of these modified nucleosides would need to develop appropriate animal models and protocols.
|
| ADME/Pharmacokinetics |
5-Aza-7-deazaguanine has a molecular weight of 151.13 and a molecular formula of C5H5N5O. The compound is soluble in water at 5 mg/mL with ultrasonic treatment and adjustment of pH to 9 with NaOH. For research use, 5-Aza-7-deazaguanine is typically stored as powder at -20degC for up to 3 years or at 4degC for up to 2 years. The compound is a synthetic purine analog and should be handled with appropriate care. Detailed pharmacokinetic parameters such as oral bioavailability, half-life, and tissue distribution have not been determined.
|
| Toxicity/Toxicokinetics |
Toxicological data for 5-Aza-7-deazaguanine are limited. As a research compound used primarily for enzymatic synthesis, 5-Aza-7-deazaguanine has not been systematically evaluated for toxicity in preclinical studies. Standard safety precautions should be followed when handling the compound, including the use of appropriate personal protective equipment. The compound is for research use only and not for human therapeutic use. Researchers should consult the Safety Data Sheet (SDS) for specific safety information.
|
| References | |
| Additional Infomation |
5-Aza-7-deazaguanine (CAS#: 67410-64-4) is a synthetic purine analog that serves as a substrate for E. coli purine nucleoside phosphorylase in the synthesis of base-modified nucleosides. It has a molecular formula of C5H5N5O and a molecular weight of 151.13. The compound is used in biochemical research for the enzymatic synthesis of modified nucleosides. 5-Aza-7-deazaguanine is not approved for clinical use and is available only for research purposes in nucleic acid chemistry and drug discovery.
|
| Molecular Formula |
C5H5N5O
|
|---|---|
| Molecular Weight |
151.1261
|
| Exact Mass |
151.049
|
| CAS # |
67410-64-4
|
| PubChem CID |
135600909
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
-1
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
11
|
| Complexity |
225
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
KSTJOICDZAFYTD-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C5H5N5O/c6-3-8-4-7-1-2-10(4)5(11)9-3/h1-2H,(H3,6,7,8,9,11)
|
| Chemical Name |
2-amino-3H-imidazo[1,2-a][1,3,5]triazin-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~5 mg/mL (~33.08 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.6168 mL | 33.0841 mL | 66.1682 mL | |
| 5 mM | 1.3234 mL | 6.6168 mL | 13.2336 mL | |
| 10 mM | 0.6617 mL | 3.3084 mL | 6.6168 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
